| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 2,477,800 | 2,279,400 | 2,534,700 | 2,645,500 |
| Gain on sale of priority review voucher, net | 0 | 0* | 0 | 0 |
| Cost of sales, excluding amortization and impairment of acquired intangible assets | 661,000 | 495,500 | 674,400 | 605,000 |
| Research and development | 539,000 | 509,400 | 436,100 | 399,000 |
| Acquired in-process research and development, upfront and milestone expense | 34,000 | 222,400 | 2,100 | 46,600 |
| Selling, general and administrative | 607,300 | 682,500 | 594,800 | 583,800 |
| Amortization and impairment of acquired intangible assets | 136,500 | 136,600 | 135,700 | 130,900 |
| Collaboration profit sharing/(loss reimbursement) | 74,200 | 69,900 | 87,200 | 75,000 |
| (gain) loss on fair value remeasurement of contingent consideration | NaN | -8,400* | NaN | NaN |
| Impairment of rou asset | NaN | 49,700* | NaN | NaN |
| Business combination, contingent consideration, change in contingent consideration, liability, increase (decrease) | 20,500 | NaN | 5,600 | 13,200 |
| Restructuring charges | 7,900 | 6,600 | 7,400 | -700 |
| Other (income) expense, net | -19,700 | -154,400 | -34,100 | -48,700 |
| Total cost and expense | 2,100,100 | 2,335,400 | 1,977,400 | 1,901,500 |
| Income before income tax (benefit) expense | 377,700 | -56,000 | 557,300 | 744,000 |
| Income tax (benefit) expense | 58,200 | -7,100 | 90,800 | 109,200 |
| Net income | NaN | -48,900* | NaN | NaN |
| Net income attributable to noncontrolling interests, net of tax | NaN | 0* | NaN | NaN |
| Net income attributable to biogen inc | 319,500 | -48,900 | 466,500 | 634,800 |
| Basic EPS | 2.17 | -0.333 | 3.18 | 4.33 |
| Diluted EPS | 2.15 | -0.33 | 3.17 | 4.33 |
| Basic Average Shares | 147,200,000 | 146,800,000 | 146,600,000 | 146,500,000 |
| Diluted Average Shares | 148,400,000 | 148,000,000 | 147,100,000 | 146,700,000 |
BIOGEN INC. (BIIB)
BIOGEN INC. (BIIB)